Basic Information
AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225 MG/1.5ML
INJECTION, SOLUTION
Regulatory Information
SIN15937P
May 8, 2020
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
June 3, 2025
XN02CD03
Company Information
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Active Ingredients
Fremanezumab
Strength: 225 mg/1.5 ml
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** AJOVY is indicated for the preventive treatment of migraine in adults.